Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 1/20 | 0.39 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16631692 | 0.91 | CYP19A1 (0.50) | KCNMA1HRH4CYP19A1MPOAMY1A | |
| SCHEMBL18080399 | 0.89 | KCNMA1 (0.54) | KCNMA1HRH4HRH3CYP19A1MPO | |
| SCHEMBL18081754 | 0.82 | CHRNE (0.35) | KCNMA1CYP19A1AMY1ACHRNE | |
| SCHEMBL18080377 | 0.81 | CYP19A1 (0.48) | KCNMA1HRH4CYP19A1MPOAMY1A | |
| SCHEMBL16631913 | 0.81 | CYP19A1 (0.52) | CYP19A1NPC1RAB9A | |
| SCHEMBL16631388 | 0.78 | KCNMA1 (0.47) | KCNMA1HRH4HRH3TK2TK1 | |
| SCHEMBL16631731 | 0.78 | KCNMA1 (0.54) | KCNMA1HRH4HRH3CYP19A1MPO | |
| SCHEMBL18081774 | 0.77 | AMY1A (0.33) | MPOAMY1A | |
| SCHEMBL16631909 | 0.77 | MAPK1 (0.34) | CHRNEHPGD | |
| SCHEMBL16631910 | 0.76 | MEN1 (0.31) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | KCNMA1 4287/4885HRH4 4824/4885HRH3 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.